Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma? Consortium for Improving Survival of Lymphoma (CISL) study

Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96–100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7–168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8–197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9–121.9 months) and the OS was 137.3 months (95 % CI 127.9–146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy.